Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant

NCT04035876 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma
Liver Transplant

Interventions

DRUG: Camrelizumab plus apatinib

Sponsor

Zhejiang University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]